Summary
Core view: Laurus Labs delivered its highest-ever quarterly revenue and profit in Q1 FY27, with CDMO revenue up 69% year-on-year driving a 7-point EBITDA margin expansion to 31.8% and PAT up 125%. The result is a genuine mix-led improvement rather than a one-off, but a single CDMO order cycle can be lumpy, and the market is already pricing in sustained record margins.
Laurus is an integrated API, generics and CDMO company with growing exposure to biologics and gene-therapy manufacturing. The CDMO segment's rapid growth is the key swing factor in both revenue and margin, alongside the base generic-API and ARV businesses.
Q1 FY27 Snapshot
Revenue₹2,026 Cr+29% YoY
EBITDA₹644 CrMargin 31.8%
PAT₹367.6 Cr+125% YoY
ROCE19.0%vs 17.7% YoY
| Metric | Q1 FY26 | Q1 FY27 |
|---|---|---|
| Gross margin | 59.4% | 62.7% |
| EBITDA margin | 24.8% | 31.8% |
| R&D spend | Not disclosed | ₹118 Cr (5.8% of revenue) |
Business Quality And Mix
Strengths
- CDMO segment grew 69% YoY, becoming the key earnings driver.
- Gross margin expanded to 62.7%, reflecting a richer product mix.
- Growing biologics and gene-therapy manufacturing optionality.
- Return on capital employed improved to 19%.
Constraints
- CDMO revenue can be lumpy, tied to a relatively small number of large customer programs.
- Base generic-API and ARV pricing remains competitive.
- High R&D intensity requires continued reinvestment.
- Valuation already prices in a sustained record margin.
Growth Drivers And Capacity Economics
CDMO growth+69% YoYQ1 FY27
Gross margin62.7%Up 330 bps YoY
R&D5.8% of revenue₹118 Cr
Growth is being driven by CDMO project wins in small molecules and an expanding biologics/gene-therapy pipeline, alongside steady demand in the base API and generics business. Capacity built in prior years is now seeing better utilisation.
Management Guardrails And Credibility
| Objective | Target | Assessment |
|---|---|---|
| Margin sustainability | Sustain a mid-to-high-20s% EBITDA margin | Q1's 31.8% is a record; management has not guided this as the new steady-state, so some moderation is likely. |
| CDMO growth | Continue double-digit CDMO growth | 69% YoY growth is exceptional and unlikely to repeat every quarter; base-rate growth is the more durable expectation. |
| Capex | Continued investment in biologics/gene therapy | Adds long-dated optionality but requires sustained R&D and capex spend. |
Financial Quality
TTM P/E~46xAnalyst approximation
ROCE19.0%Improving
Gross margin62.7%Record
EBITDA margin31.8%Record
| Quality test | Reading | Interpretation |
|---|---|---|
| Earnings quality | PAT +125% YoY on CDMO mix shift | Genuine operating improvement, but a single-quarter mix benefit should not be annualised without moderation. |
| Margin durability | EBITDA margin 31.8% vs 24.8% YoY | A 7-point jump this large is unlikely to be the new permanent base; some reversion is a reasonable base case. |
| Capital efficiency | ROCE 19% vs 17.7% YoY | Improving trend supports the quality of the earnings recovery. |
Valuation
Key Risks
- CDMO order lumpiness and customer concentration.
- Margin reversion from the Q1 FY27 peak.
- Competitive pricing in base API/ARV business.
- Execution risk in scaling biologics/gene-therapy capacity.
- Premium valuation leaves little room for disappointment.
Projection: Next 2-4 Quarters
Investor Watchlist
- CDMO order intake and customer concentration.
- Gross and EBITDA margin trend versus the Q1 FY27 peak.
- Biologics/gene-therapy revenue contribution.
- R&D spend as a percentage of revenue.
- ROCE trend.